

Supplementary Table S1. Baseline clinical characteristics of patients with FGFR2-altered intrahepatic cholangiocarcinoma (N=82).

Clinical Characteristics (N=82 patients)	N	%
FGFR2 Alteration		
Fusion/Rearrangement	77	94%
Amplification	2	2.4%
Extracellular Domain In-Frame Deletion	2	2.4%
Point Mutation	1	1.2%
FGFR Inhibitor		
Reversible	37/82	45%
Pemigatinib (INCB054828)	10	12%
Infigratinib (BGJ398)	9	11%
Zoligratinib (Debio1347)	1	1.2%
Unknown	17	21%
Irreversible	36/82	44%
Futibatinib (TAS-120) [1 st FGFR inhibitor]	26	32%
Futibatinib (TAS-120) [Unknown status]	10	12%
Reversible then Irreversible	6/82	7.3%
Infigratinib then Futibatinib	3	3.7%
Zoligratinib then Futibatinib	2	2.4%
Unknown then Futibatinib	1	1.2%
Unknown	3/82	3.7%